These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12186378)

  • 21. Exemestane: a novel aromatase inactivator for breast cancer.
    Jones SA; Jones SE
    Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the use of aromatase inhibitors in breast cancer.
    Brueggemeier RW
    Expert Opin Pharmacother; 2006 Oct; 7(14):1919-30. PubMed ID: 17020418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
    Michaud LB; Buzdar AU
    Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
    Goss PE
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):487-93. PubMed ID: 14623548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of aromatase inactivators in the treatment of breast cancer.
    Lønning PE
    Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
    Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatase inhibitors: new endocrine treatment of breast cancer.
    Brueggemeier RW
    Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
    Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
    Crucitta E; Fornier MN; Locopo N; Silvestris N; Lorusso V; De Lena M
    Int J Oncol; 2002 Jun; 20(6):1283-8. PubMed ID: 12012011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase inhibitors in the treatment of breast cancer.
    Brueggemeier RW; Hackett JC; Diaz-Cruz ES
    Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
    Traina TA; Poggesi I; Robson M; Asnis A; Duncan BA; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler MN
    Breast Cancer Res Treat; 2008 Sep; 111(2):377-88. PubMed ID: 17952589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aromatase, aromatase inhibitors, and breast cancer.
    Brueggemeier RW
    Am J Ther; 2001; 8(5):333-44. PubMed ID: 11550075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
    Mortimer JE; Urban JH
    Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
    Miller WR; Bartlett J; Brodie AM; Brueggemeier RW; di Salle E; Lønning PE; Llombart A; Maass N; Maudelonde T; Sasano H; Goss PE
    Oncologist; 2008 Aug; 13(8):829-37. PubMed ID: 18695261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
    Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
    Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor].
    Tahara M; Nomura S; Hashimoto M
    Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):345-54. PubMed ID: 14501171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
    Van Asten K; Neven P; Lintermans A; Wildiers H; Paridaens R
    Endocr Relat Cancer; 2014 Feb; 21(1):R31-49. PubMed ID: 24434719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.